HB - NCIR - Artigos
Permanent URI for this collection
Browse
Browsing HB - NCIR - Artigos by Author "Almeida, R"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- Gliosarcoma with neuroaxis metastases.Publication . Ramos, R; Morais, N; Silva, AI; Almeida, RGliosarcomas are rare tumours of the central nervous system, with a well-known capacity for metastasis. When they metastasise, the dissemination occurs more frequently via the haematogenous route to extraneural sites. Metastasis-spread through the cerebrospinal fluid is extremely rare. We present the case of a 58-year-old man who underwent a gross total resection of a lesion in the left temporal lobe. The histological findings revealed a gliosarcoma and the patient received radiotherapy followed by chemotherapy. Seven months after surgery, while the patient remained neurologically intact, brain and spinal cord MRI revealed tumour recurrence and neuroaxis metastases through the traffic routes of the cerebrospinal fluid. The patient died 8 months after the diagnosis. A PubMed search regarding metastatic gliosarcoma up to June 2015 was also carried out. To the best of our knowledge, this is the first case report of gliosarcoma metastases to the brain and spinal cord leptomeninges.
- Impact of EGFR genetic variants on glioma risk and patient outcomePublication . Costa, BM; Viana-Pereira, M; Fernandes, R; Costa, S; Linhares, P; Vaz, R; Pinheiro, C; Lima, J; Soares, P; Silva, A; Pardal, F; Amorim, J; Nabiço, R; Almeida, R; Alegria, C; Pires, MM; Pinheiro, C; Carvalho, E; Oliveira, P; Lopes, JM; Reis, RMBACKGROUND: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is frequently implicated in human tumors. Three EGFR polymorphisms have been described as having a transcriptional regulatory function: two single-nucleotide polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic (CA)(n) microsatellite sequence in intron 1. We aimed to elucidate the roles of these EGFR polymorphisms in glioma susceptibility and prognosis. METHODS: We conducted a case-control study with 196 patients with glioma and 168 cancer-free controls. Unconditional multivariate logistic regression models were used to calculate ORs and 95% confidence intervals. A Cox regression model was used to evaluate associations with patient survival. False-positive report probabilities were also assessed. RESULTS: None of the EGFR -216G/T variants was significantly associated with glioma risk. The -191C/A genotype was associated with higher risk for glioma when the (CA)(n) alleles were classified as short for ≤16 or ≤17 repeats. Independently of the (CA)(n) repeat cutoff point used, shorter (CA)(n) repeat variants were significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma. In all tested models with different (CA)(n) cutoff points, only -191C/A genotype was consistently associated with improved survival of patients with glioblastoma. CONCLUSIONS: Our findings implicate EGFR -191C/A and the (CA)(n) repeat polymorphisms as risk factors for gliomas, and suggest -191C/A as a prognostic marker in glioblastoma. IMPACT: Our data support a role of these EGFR polymorphisms in determining glioma susceptibility, with potential relevance for molecularly based stratification of patients with glioblastoma for individualized therapies
- Incisão sublabial versus columelar no acesso trans-septal para cirurgia trans-esfenoidal microscópica da hipófise. Estudo retrospectivoPublication . Guimarães, J; Santos, J; Miranda, D; Carvalho Moreira, F; Marçal, N; Pereira, G; Marques, O; Almeida, R; Vilarinho, S; Frias, A; Alegria, C; Pratas, RObjectivos: Comparar a incisão sublabial com a incisão columelar no acesso trans-septal para cirurgia trans- -esfenoidal microscópica da hipófise, quanto às complicações perioperatórias e sequelas observadas. Desenho do estudo: Estudo retrospectivo. Material e métodos: Revisão dos registos clínicos de 50 doentes submetidos a cirurgia trans-esfenoidal microscópica para ressecção de adenoma da hipófise, no Hospital de Braga, entre Julho de 2007 e Novembro de 2010. Foram colhidos e avaliados dados demográficos, co-morbilidades pré-operatórias, classificações histológica e imagiológica do adenoma, duração da cirurgia, duração do internamento e complicações per(pré)- e pós-operatórias. O seguimento dos doentes foi entre um e seis meses. Na análise estatística foi utilizado o programa SPSS® Statistics 17.0. Resultados: 50 doentes, 32 (64%) do sexo feminino e 18 (36%) do sexo masculino, com idades compreendidas entre os 16 e 87 anos, média de 50 anos. 40 (80%) casos tratavam-se de macroadenomas e 10 (20%) de microadenomas. 15/47 (31.9%) doentes foram submetidos a cirurgia trans-esfenoidal transseptal através de incisão columelar e 32/47 (68.1%) doentes através de incisão sublabial. Verificaram-se complicações oronasais num total de 5/14 (35.7%) doentes no grupo em que foi utilizada incisão columelar e 14/29 (48.3%) doentes no grupo em que foi utilizada incisão sublabial (p>0.05). Verificou-se que doentes com excesso de peso tiveram mais frequentemente complicações (p<0.01). Não se verificaram diferenças estatisticamente significativas na taxa de doentes com complicações de acordo com a idade, género, incisão cirúrgica utilizada, tipo de adenoma, ou em doentes com outras co-morbilidades pré-operatórias. A duração da cirurgia e do internamento não tiveram diferenças estatisticamente significativas relativamente à incisão cirúrgica utilizada. Conclusões: As incisões sublabial e columelar na cirurgia trans-esfenoidal mostraram, neste estudo, não afectar as taxas de complicações per(pré)- e pós-operatórias. Título abreviado: Cirurgia trans-esfenoidal da hipófise Palavras-chave: cirurgia trans-esfenoidal, cirurgia da hipófise, complicações da cirurgia da hipófise, adenoma da hipófise.
- Macroprolactinomas: avaliação da resposta aos agonistas dopaminérgicosPublication . Santos, MJ; Almeida, R; Marques, O
- Primary Bilateral Thalamic Astrocytoma Presenting With Head Tremor, Ataxia, and DementiaPublication . Machado, A; Ribeiro, M; Rodrigues, M; Ferreira, C; Almeida, R; Santana, I; Castro, L; Carpenter, S
- Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre studyPublication . Costa, BM; Caeiro, C; Guimarães, I; Martinho, O; Jaraquemada, T; Augusto, I; Castro, l; Osório, L; Linhares, P; Honavar, M; Resende, M; Nabiço, R; Almeida, R; Alegria, C; Pires, M; Pinheiro, C; Carvalho, E; Lopes, JM; Costa, P; Damasceno, M; Reis, RMGlioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol). The Kaplan-Meier method was used to construct survival curves, and the log-rank test and a Cox-regression model were used to analyze patient survival. The methylation status of MGMT was successfully determined in 89% (80/90) of the tumors. The frequency of tumoral MGMT promoter methylation was 47.5%. The median overall survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13 months (95% CI 13.3-18.7) for patients whose tumors had a methylated or unmethylated MGMT, respectively. Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test). None of the patient clinical features were significantly correlated with survival. This is the first study to report the frequency of MGMT methylation among Portuguese GBM patients. Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide. Additional robust prospective studies are warranted to clarify whether the MGMT status should be used in clinical decisions.
- A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System LymphomaPublication . Ramos, R; Fernandes, JS; Almeida, M; Almeida, RPrimary central nervous system lymphoma remission after steroid treatment is a well-known phenomenon, but remission without any type of treatment is extremely rare. We present a rare case of spontaneous remission of a diffuse large B-cell lymphoma of the central nervous system as well as its subsequent reappearance in another location. The atypical presentation misled the neurosurgeons and neurologists, delaying diagnosis and treatment. The patient underwent brain biopsy after the relapse and started radiotherapy and chemotherapy with cytarabine + methotrexate + rituximab. As of 32 months after the diagnosis, the patient remained asymptomatic, with no focal neurological deficits and the disease in complete remission. A PubMed search of the literature up to June 2017 regarding spontaneous remission central nervous system lymphoma was also carried out.
- Ten-year follow-up of a giant prolactinomaPublication . Fernandes, V; Santos, MJ; Almeida, R; Marques, OGiant prolactinomas are rare pituitary tumours of which management can be a challenge. A 28-year-old man presented with headaches, visual impairment and behavioural changes. Clinically, the patient was found to have hypogonadism and bitemporal hemianopsia. A MRI demonstrated a pituitary tumour 76 mm in diameter and blood tests revealed a serum prolactin of 158 700 µU/mL (reference range 58-254). Initially, a craniotomy was performed. Immunohistochemistry of the tumour identified a prolactinoma with a high proliferative index and the patient was started on treatment with a dopamine agonist. A year later, neurological symptoms worsened due to regrowth of the lesion's cystic component, and so further surgery was performed. After 10 years of treatment with dopamine agonists, the prolactin levels decreased by 96.8%, there was an effective reduction in tumour size, and the neurological signs and symptoms resolved.